Speaker Profile
Mitchell P. Rosen

Mitchell P. Rosen MD, HCLD

Reproductive Endocrinology, Fertility
San Francisco, California, United States of America

Connect with the speaker?

Dr. Mitch Rosen, of UCSF is an expert in reproductive endocrinology and fertility based in San Francisco. He is a fertility physician at the UCSF Center for Reproductive Health as well as an Associate Professor at UCSF, where he teaches medical students, residents, and fellows. Dr. Rosen also serves as the Director of the UCSF Fertility Preservation Program, which helps patients with cancer preserve their ability to have children, despite aggressive cancer treatment. Rosen and his team of experienced and compassionate health care professionals are leading experts in the field of fertility preservation. Dr. Mitch Rosen graduated from Saint Louis University School of Medicine in 1998. He attended the University of Texas Medical Branch in Galveston, (Texas) where he completed his residency in obstetrics and gynecology. He was named the best resident twice and received the Ortho-McNeil Best Resident Teacher Award.

In 2002, Rosen entered his fellowship training in reproductive endocrinology and infertility at UCSF. During his fellowship, Rosen explored a basic research interest in genes involved in gametogenesis. Dr. Rosen was also trained in the UCSF embryology laboratory and is a high complexity lab director (HCLD). At UCSF, Mitch Rosen has recently received funding to develop a randomized trial evaluating concomitant FSH with hCG for ovulation trigger. During a spontaneous ovulatory surge, there is a rise in both FSH and LH. While hCG has been substituted for the LH surge, no studies have addressed the role of FSH on the developing oocyte during the final steps of nuclear and cytoplasmic maturation. This prospective study will compare ovarian stimulation and follicular development, along with oocyte maturation, developmental competence, and quality between those participants receiving hCG alone or combined FSH/hCG. In addition, the intrafollicular hormonal milieu, embryo quality, and pregnancy rates will be compared between the two treatment groups.

EVENTS & ACTIVITIES (Speaking, Spoken, and Authored)